Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

750 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-15

Study Completion Date

2021-03-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions.

The CMx platform has been showed to be able to the detection of Circulating Tumor Cells (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this study goals are: 1) to establish a standard detection process utilizing the Automated Liquid Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440

Colorectal Cancer Colorectal Neoplasms Colorectal Polyp +15 more

RECRUITING

Feasibility Trial of Magnetic-assisted Colonoscope Platform

NCT05213741

Colonoscopy Colorectal Cancer

UNKNOWN NA

Evaluation of a Point-of-care Testing Instrument for Fecal Immunochemical Test

NCT05232721

Colorectal Cancer

UNKNOWN

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

NCT03789162

Colorectal Cancer

COMPLETED

A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence

NCT02005913

Colorectal Cancer (CRC)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Selection of patients:

A. The disease group includes 300 patients diagnosed with stages 0-4 colorectal cancer not previously treated.

B. The control group includes 450 control subjects who will undergo a colonoscopy procedure.
2. Study stages

Stage I: The laboratory manually analyzes circulating tumor cells to establish a standard detection process for Automated Liquid Biopsy System

Stage II: Comparison analysis between manual and Automated Liquid Biopsy Platform, establishing the procedural and analytical models for the Automated Liquid Biopsy Platform

Stage III: Verification of the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.
3. Methods

I. CTC isolation Peripheral blood drawn from subjects will be processed using the CMx platform or the automated liquid biopsy system for detection and capture.

II. Characterization of isolated CTC using Immunofluorescence Staining

III. CRC-related gene expression The serum and circulating tumor cells isolated from the blood will be used to extract RNA, and then be analyzed with the expression of different genes by real-time quantitative polymerase chain reaction (real-time PCR).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colo-rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Disease Group

The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.

No interventions assigned to this group

Control Group

The control group will receive Colonoscopy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
* 2\. The control group will receive Colonoscopy
* 3\. Above 20 years old

Exclusion Criteria

* 1\. Refuse to sign the informed consent form
* 2\. Received surgery within one month
* 3\. Previous cancer history
* 4\. Autoimmune diseases
* 5\. Chronic inflammatory diseases
* 6\. Acute inflammatory or infectious diseases in three months
* 7\. Myelodysplastic syndromes and myeloproliferative disorder
* 8\. Other diseases decided by PI

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes